Ê×Ò³| Â鶹´«Ã½Ó³»­

Up to 50 percent of people in the U.S. with Alzheimer’s receive an imprecise or inaccurate diagnosis of their cognitive condition. The tools typically used to detect the disease, like a PET scan, can cost thousands of dollars and are generally only available in places with large medical institutions. And African Americans are 35 percent less likely to be diagnosed than their White counterparts.

More than 6.7 million individuals in the U.S. have Alzheimer’s disease, and that number is growing rapidly. Each day that passes without effective treatments brings tragic consequences for patients and their loved ones. As the debate over coverage for new Alzheimer’s drugs continues, Dr. Jeffrey Cummings of the Ê×Ò³| Â鶹´«Ã½Ó³»­, joined us to discuss the challenging path that led to these medicines, the state of the science now, and hope for the future.

KNX In Depth's Charles Feldman and Rob Archer discuss a new study that looks into Alzheimer's research and drugs. It sounds optimistic when it comes to the future of treating the disease.

More than 6 million Americans are living with Alzheimer's disease, a staggering number that's expected to double within the next 30 years.

Could changing your diet play a role in slowing or even preventing the development of dementia? We're one step closer to finding out, thanks to a new UNLV study that bolsters the long-suspected link between gut health and Alzheimer's disease.

Lighthouse Pharmaceuticals, a clinical-stage pharmaceutical company developing therapeutics to alter the course of dementia and other degenerative diseases, announced completion of a Pre-investigational New Drug meeting with the Food and Drug Administration related to the planned Phase 2b clinical study of LHP588 and the formation of its Clinical Advisory Board (CAB). The CAB includes six members with diverse backgrounds and expertise in dementia, Alzheimer’s disease, inflammation, neurodegenerative disorders, and drug development.

A new drug shows promising results in trials, but questions remain about whether benefits outweigh side effects.

Findings suggest that the amyloid-targeting drug candidate slows cognitive decline in some people, but questions remain over its potential side effects